GGrantIndex
← Search

Accelerated Aging and Anal Cancer Risk among People Living with HIV

$257,182P30FY2023CANIH

Vanderbilt University Medical Center, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

VANDERBILT-INGRAM CANCER CENTER OVERALL PROJECT SUMMARY/ABSTRACT This is the fifth competing renewal of the Cancer Center Support Grant (CCSG) at Vanderbilt-Ingram Cancer Center (VICC). VICC is a matrix center within Vanderbilt University Medical Center and Vanderbilt University that integrates the cancer-related expertise and resources of the Schools of Medicine, Nursing, Arts and Sciences and Engineering, the Peabody School of Education and the fully integrated Veterans Administration Medical Center. The major clinical facilities and the majority of research facilities are located on one campus, which promotes informal interactions, sharing of resources and productive collaborations. Established in 1993, VICC functions as an organizational unit with a supra-departmental status. VICC-specific responsibilities and aims are 1) to conduct, support and enhance state-of-the-art, multidisciplinary basic, clinical and population- based research; 2) to coordinate and integrate cancer-related activities across Vanderbilt and to collaborate with our local, regional, national and global partners; 3) to train and develop the next generation of cancer investigators, cancer leaders and the continuum of cancer care providers; and 4) to assess and prioritize community needs and to leverage partnerships to address those needs through cancer research, care and control activities. The research, training, and community outreach and engagement objectives are accomplished through CCSG and institutionally supported organizational capabilities, planning and evaluation, and eight research programs. The VICC Research Programs are Signal Transduction and Cell Proliferation, Genome Maintenance, Host-Tumor Interactions, Gastrointestinal Cancer, Translational Research and Interventional Oncology, Breast Cancer, Cancer Epidemiology, and Cancer Health Outcomes and Control. Eleven shared resources are proposed, all previously supported. Remarkable VICC growth and scientific discovery over the past project period has led to 22 new multi-investigator grants for a total of 71, and 8 new training grants for a total of 26. In addition, two NCI SPOREs were successfully renewed. With these and many other NCI grants, peer-reviewed funding increased 35%. Significant accomplishments have been made in precision oncology, cancer epidemiology, health outcomes and control, genomics, cancer drug discovery, early detection and prevention, and cancer disparities research. Increased VICC space and facilities, along with philanthropic and institutional funds, supported the recruitment of 67 new faculty, who join a dedicated team carrying out the VICC mission: to alleviate cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention, education and community initiatives. VICC senior leadership provides effective oversight and catalyzes innovative and paradigm-shifting science that translates to benefit for our patients and the community we serve in our catchment and reduces the burden of cancer nationally and globally.

View original record on NIH RePORTER →
Accelerated Aging and Anal Cancer Risk among People Living with HIV · GrantIndex